Alopecia Areata Market Size in the 7MM was ~USD 379 Million in 2023, it is expected to grow at a CAGR of 21.2% by 2034, estimates DelveInsight

Analysis indicates that the alopecia market size in the 7 major markets (7MM) was valued at approximately USD 379 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 21.2% between 2024 and 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Alopecia Areata landscape.

The alopecia areata market is projected to see steady growth, with a strong compound annual growth rate (CAGR) expected from 2024 to 2034. Expansion across the 7 major markets (7MM) will be driven by the launch of new therapies, including RINVOQ (upadacitinib), coacillium (LH-8), bempikibart, Rezpegaldesleukin (NKTR-358), and others. According to DelveInsight, approximately 1.7 million diagnosed prevalent cases of alopecia areata were reported across the 7MM in 2023, with the United States accounting for about 35% of cases, the EU4 and UK together representing nearly 49%, and Japan contributing around 16%.

Eli Lilly and Company, Incyte Corporation, Pfizer, and Sun Pharmaceuticals are recognized as major players in the alopecia market, offering approved therapies such as OLUMIANT in the US, EU, and Japan; LITFULO in the US, EU, and Japan; and LEQSELVI in the United States.

In 2023, the U.S. alopecia areata market was valued at around USD 202 million, representing approximately 53% of the total global market, and is expected to grow significantly with the introduction of new and emerging therapies. The combined market in the EU4 and the UK was estimated at about USD 146 million, accounting for nearly 39% of total revenue across the 7 major markets (7MM). Within this region, the UK held the largest share at roughly USD 51 million, followed by Spain at around USD 28 million, while France recorded the smallest market size at approximately USD 20 million. In 2023, Japan’s alopecia areata market was valued at about USD 31 million and is anticipated to expand over the forecast period from 2024 to 2034.

In 2023, the United States reported the highest prevalence of alopecia areata, with approximately 764 thousand cases, projected to grow at a CAGR of 1.4% through 2034. Within the EU4 and the UK, the UK had the largest number of diagnosed prevalent cases at around 323 thousand, followed by Spain with roughly 170 thousand cases, while Italy recorded the lowest at about 100 thousand. In Japan, 2023 saw approximately 167 thousand diagnosed cases in females and 107 thousand in males, with both expected to increase by 2034.

In 2023, females accounted for 63% of alopecia areata cases in the EU4 and the UK, while males represented 37%. These gender trends are expected to persist, with overall prevalence projected to increase by 2034.

DelveInsight’s report “Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Alopecia Areata landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Alopecia Areata market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Alopecia Areata market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alopecia Areata Market Forecast

Some of the key facts of the Alopecia Areata Market Report:

• Key Alopecia Areata Companies: Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others
• Key Alopecia Areata Therapies: OLUMIANT (baricitinib), LITFULO (ritlecitinib), Etrasimod, Coacillium (LH-8), PF-06651600, ADX-914, Upadacitinib, Daxdilimab, CTP-543, Deucravacitinib, SHR0302, IMG-007, Jaktinib, Rezpegaldesleukin, Rosnilimab, LEO 124249, Baricitinib, and others
• The Alopecia Areata epidemiology based on gender analyzed that females and males are equally affected by Alopecia Areata
• The Alopecia Areata epidemiology based on gender analyzed that Alopecia Areata affects both males and females equally

Alopecia Areata Overview

Alopecia Areata is an autoimmune disorder that causes sudden, patchy hair loss on the scalp, face, or other parts of the body. The immune system mistakenly attacks hair follicles, leading to hair thinning or bald spots. It can affect people of all ages and genders and may range from small patches to complete hair loss (alopecia totalis) in severe cases. While the exact cause is unknown, genetics, environmental triggers, and immune system dysfunction play a role. Hair may regrow spontaneously, but recurrence is common.

Get a Free sample for the Alopecia Areata Market Report:

https://www.delveinsight.com/report-store/alopecia-areata-market

Key Trends in Alopecia Areata Therapeutics Market:

• Rapid growth of targeted biologics, especially JAK inhibitors: Therapies like baricitinib, ritlecitinib and deuruxolitinib are transforming treatment by targeting immune pathways that drive hair loss, gaining regulatory approvals and becoming preferred options over traditional corticosteroids.
• Emergence of novel immune-modulating and precision therapies: Beyond JAKs, next-gen agents such as OX40L inhibitors, IL-2 modulators and other small molecules are in clinical development to offer more specific and potentially safer long-term disease control.
• Shift toward personalized and non-invasive treatments: There’s growing interest in tailoring therapy based on patient genetics and disease profile, along with demand for topical, low-risk options and remote care models that improve accessibility and reduce side effects.
• Expanding global market access and awareness: Increasing disease prevalence, heightened public awareness and better healthcare infrastructure in emerging regions are broadening the patient pool and driving adoption of advanced therapies. 
• Challenges from cost and variability in response: High prices of biologics and variable patient responses are encouraging development of more cost-effective solutions and patient support programs to boost real-world uptake.

Alopecia Areata Epidemiology

The Alopecia Areata epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alopecia Areata Epidemiology Segmentation:

The Alopecia Areata market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Alopecia Areata
• Prevalent Cases of Alopecia Areata by severity
• Gender-specific Prevalence of Alopecia Areata
• Diagnosed Cases of Episodic and Chronic Alopecia Areata

Download the report to understand which factors are driving Alopecia Areata epidemiology trends @ Alopecia Areata Epidemiological Insights

Recent Development In The Alopecia Areata Treatment Landscape:

• In January 2026, Legacy Healthcare announced its plans to advance the topical solution Cinainu into a multi-regional Phase 3 trial (RAAINBOW-2) for patients with moderate to severe alopecia areata (AA) following FDA clearance. The FDA approved the company’s IND application for Cinainu, enabling the botanical drug candidate to move forward with an international Phase 3 study in moderate to severe AA patients to support a future New Drug Application (NDA). This FDA clearance comes after the successful completion of the international Phase 2/3 RAAINBOW study in children and adolescents with moderate-to-severe AA, as well as agreement from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to include Japanese adult and pediatric patients (from age 2) in the global Phase 3 trial to support registration in Japan. Discussions with additional health authorities are planned to expand the RAAINBOW-2 trial to more regions.
• In August 2025, AbbVie’s leading Janus kinase (JAK) inhibitor, Rinvoq (upadacitinib), achieved its primary endpoints in a second Phase III trial for alopecia areata. In Study 1 of the UP-AA program (NCT06012240), the therapy showed a significant improvement in scalp hair regrowth, with 45.2% of patients on the 15mg dose and 55% on the 30mg dose reaching 80% scalp hair coverage after 24 weeks of treatment, as assessed using the Severity of Alopecia Tool (SALT) scores.
• In July 2025, AbbVie (NYSE: ABBV) has announced positive topline results from the first of two pivotal Phase 3 UP-AA clinical trials, which are assessing the safety and effectiveness of upadacitinib (RINVOQ®; 15 mg and 30 mg once daily) in adults and adolescents with severe alopecia areata (AA). Participants in the study had a mean baseline SALT score of 83.8, indicating roughly 16% scalp hair coverage.
• In May 2025, A siRNA-based treatment for alopecia areata, developed by researchers Anastasia Khvorova, PhD; John Harris, MD, PhD’05; Julia Alterman, PhD; and Qi Tang, PhD, at UMass Chan Medical School and licensed to Alys Pharmaceuticals Inc., has now been administered to the first participant in a Phase IIa clinical trial. Alys Pharmaceuticals—a Boston-based biotech company formed through the merger of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, NIRA Biosciences, and Vimela Therapeutics is advancing ALY-101, its first clinical candidate from a pipeline of siRNA therapies focused on dermatology.
• In March 2025, Findings from the Phase III BRAVE-AA-PEDS trial (NCT05723198) reveal that adolescents with severe alopecia areata (AA) treated with once-daily baricitinib (Olumiant) saw substantial hair regrowth on the scalp, eyebrows, and eyelashes after 36 weeks. Remarkably, the data suggest that this younger group responded more quickly to baricitinib than adult patients with severe AA.
• In March 2025, Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) have announced late-breaking results from the Phase 3 BRAVE-AA-PEDS study, showing that adolescents (ages 12 to under 18) with severe alopecia areata (AA) experienced significant hair regrowth on the scalp, eyebrows, and eyelashes after 36 weeks of once-daily oral treatment with baricitinib at 4 mg and 2 mg doses. These findings were presented during a late-breaker session at the American Academy of Dermatology (AAD) Annual Meeting.
• In February 2025, Q32 Bio halted its Phase II trial for its former lead renal disease candidate as it shifts focus to its alopecia areata treatment, bempikibart, following a corporate restructuring and workforce reductions. The U.S.-based company confirmed the cancellation of its Phase II renal basket trial (NCT06419205) for ADX-097, a humanized anti-C3d mAb fusion protein. Instead, Q32 Bio plans to launch an open-label extension of its Phase II SIGNAL-AA trial (NCT06018428).

Alopecia Areata Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alopecia Areata market or expected to get launched during the study period. The analysis covers Alopecia Areata market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alopecia Areata Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alopecia Areata Therapies and Key Companies

• OLUMIANT (baricitinib): Eli Lilly and Company/Incyte Corporation
• LITFULO (ritlecitinib): Pfizer
• Etrasimod: Pfizer
• Coacillium (LH-8): Legacy Healthcare
• PF-06651600: Pfizer
• ADX-914: Q32 Bio Inc.
• Upadacitinib: AbbVie
• Daxdilimab: Amgen
• CTP-543: Concert Pharmaceuticals
• Deucravacitinib: Bristol-Myers Squibb
• SHR0302: Reistone Biopharma
• IMG-007: Inmagene LLC
• Jaktinib: Suzhou Zelgen Biopharma
• Rezpegaldesleukin: Nektar Therapeutics
• Rosnilimab: AnaptysBio, Inc.
• LEO 124249: LEO Pharma
• Baricitinib: Eli Lilly and Company

To know more about Alopecia Areata treatment, visit @ Alopecia Areata Medications

Alopecia Areata Market Drivers

• Increasing prevalence and patient awareness: The global incidence of alopecia areata is rising, and greater public knowledge of autoimmune hair loss is prompting more individuals to seek diagnosis and treatment.
• Advancements in targeted therapies (especially JAK inhibitors): The development and approval of novel targeted treatments like JAK inhibitors and biologics are improving clinical outcomes and expanding therapeutic options beyond traditional corticosteroids.
• Growth in R&D and personalized medicine approaches: Enhanced understanding of autoimmune mechanisms and precision medicine strategies is driving innovation and tailored treatments for diverse patient subgroups.
• Expansion of healthcare access and telemedicine: Emerging teledermatology services and broader specialist access are helping patients in remote or underserved regions obtain earlier diagnosis and treatment plans.
• Social emphasis on aesthetics and quality of life: Rising demand for effective hair regrowth solutions and cosmetic improvements is encouraging treatment uptake and market growth.

Alopecia Areata Market Barriers

• High cost of advanced therapies and limited reimbursement: Innovative treatments like JAK inhibitors and biologics are often expensive and not fully covered by insurance, restricting affordability and access, especially in developing regions.
• Variable treatment response and lack of long‑term efficacy data: Patients respond differently to therapies, and limited long‑term safety/effectiveness evidence can hinder confidence and adoption rates.
• Limited access in low‑resource markets: Healthcare infrastructure gaps, logistical challenges, and low awareness in parts of Asia, Africa, and Latin America reduce treatment reach for many patients.
• Side effects and safety concerns: Some treatments carry risks (e.g., immunosuppression with systemic therapies), which may deter use and require careful monitoring.
• Regulatory and clinical development hurdles: Complex, costly clinical trials and regulatory processes can delay the introduction of new therapies and slow market expansion.

Scope of the Alopecia Areata Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Alopecia Areata Companies: Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others
• Key Alopecia Areata Therapies: OLUMIANT (baricitinib), LITFULO (ritlecitinib), Etrasimod, Coacillium (LH-8), PF-06651600, ADX-914, Upadacitinib, Daxdilimab, CTP-543, Deucravacitinib, SHR0302, IMG-007, Jaktinib, Rezpegaldesleukin, Rosnilimab, LEO 124249, Baricitinib, and others
• Alopecia Areata Therapeutic Assessment: Alopecia Areata current marketed and Alopecia Areata emerging therapies
• Alopecia Areata Market Dynamics:  Alopecia Areata market drivers and Alopecia Areata market barriers
• Alopecia Areata Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Alopecia Areata Unmet Needs, KOL’s views, Analyst’s views, Alopecia Areata Market Access and Reimbursement

Discover more about therapies set to grab major Alopecia Areata market share @ Alopecia Areata Treatment Landscape

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.